| "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" |
Ongoing |
Ertugliflozin |
3 |
MK-8835-059-00 |
KSH |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial |
Completed |
Luspatercept (ACE 536) |
3 |
ACE-536-B-THAL-001 |
KKUH |
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. |
Terminated |
Prasugrel |
3 |
H7T-MC-TADO |
KAUH-J |
| A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE |
Completed |
PF-06651600 |
2a |
B7981007 |
NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah) |
| "A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease " |
Ongoing |
Guselkumab |
2 |
CNTO1959CRD3001 |
KAMC |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care |
Completed |
KB195 |
2 |
K020-218 |
KKUH |
| A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations |
Ongoing |
AAV-hHA-hMUT |
1, IIIb |
LB001-001 |
King Abdulaziz Medical City NG (Riyadh) |
| A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS |
Ongoing |
DEXMEDETOMIDINE |
3 |
RAC# 21901310 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies " |
Ongoing |
HYDROXYUREA (HYDROXYCARBAMIDE) |
3 |
CT20/008/R |
King Abdulaziz Medical City NG (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Ongoing |
Convalescent Plasma |
2 |
20-COVID-19-01M |
KFSH-D |